Remedium Capital Partners, LLC
Position in APGE — Apogee Therapeutics, Inc.
CIK 2104501
FORT LAUDERDALE, FL
Position in APGE
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$77,871,496
+$28,750,642 QoQ
Shares Held
586,691
+0.5% QoQ
Ownership
0.775%
of shares outstanding
% of Portfolio
17.24%
of 13F equity value
Holder Rank
#28
of 285 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Remedium Capital Partners, LLC holds $451,627,233 across 6 Biotechnology names. APGE ranks #3 (17.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ORKA |
Oruka Therapeutics, Inc.
|
1,565,661 | $149,003,957 | |
| 2 | SYRE |
Spyre Therapeutics, Inc.
|
1,464,169 | $129,988,923 | |
| 3 | APGE |
Apogee Therapeutics, Inc.
This page
|
586,691 | $77,871,496 | |
| 4 | DMRA |
Damora Therapeutics, Inc.
|
2,045,473 | $53,202,752 | |
| 5 | JBIO |
Jade Biosciences, Inc.
|
1,577,750 | $35,057,605 | |
| 6 | CBIO |
Crescent Biopharma, Inc.
|
361,250 | $6,502,500 |
All Filings in APGE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $77,871,496 | 586,691 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $49,120,854 | 583,591 | Shares | Sole | 2026-05-19 | |
| 2025-12-31 | $44,049,448 | 583,591 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||